Skip to content

Effects of estrogen on prognosis of patient with diffuse axonal injury due to severe traumatic brain injury

Efficacy of estrogen on recovery of prognosis in patient with diffuse axonal injury due to severe traumatic brain injury in men 15 to 70 years old

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014091919227N1
Enrollment
Unknown
Registered
2016-01-17
Start date
2014-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse axonal injury. Diffuse brain injury

Interventions

Intervention 1: 8 micrograms of oral conjugated estrogen tablets per kg body weight, once a day until 3 days for the intervention group. Intervention 2: Not prescribed any medication for control group
Treatment - Drugs
8 micrograms of oral conjugated estrogen tablets per kg body weight, once a day until 3 days for the intervention group
Not prescribed any medication for control group.

Sponsors

Vice chanscellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
14 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Men 15 to 70 years; Diffuse axonal injury diagnosis; GCS less than or equal to 8; Hospitalization in less than 8 hours of after trauma; Having informed consent to participate in the study; Lack of talent to thromboembolism. Exclusion criteria: Sex woman; Patients with refractory seizure; History of deep vein thrombosis or infection; Any history of head trauma; Any history of brain procedure; History of ischemic lesions and hemorrhagic stroke; People prone to pulmonary thromboembolism and deep vein thrombosis; (a) smoking; (b) a family history of deep vein thrombosis and pulmonary thromboembolism; (c) heart failure; (d) inflammatory bowel disease (ulcerative colitis); (e) a history of cancer; (f) hereditary disorders are prone to blood clots

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Level of consciousness. Timepoint: Admission time, discharge time and three months after discharge. Method of measurement: Glasgow coma scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeyvan Aalizadeh, MD

Tabriz University of Medical Sciences

aalizadehkeyvan@ymail.com; mreza@tbzmed.ac.ir+98 41 3334 0830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026